Results 51 to 60 of about 1,482 (173)

Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

Dermatology and Therapy, 2023
Introduction Alopecia areata (AA) is an autoimmune disease with an underlying immuno-inflammatory pathogenesis. Treatments can include systemic corticosteroids and immunomodulators (such as Janus kinase inhibitors); these medications may be associated ...
Prethibha George, Oladayo Jagun, Qing Liu, Charles Wentworth, Lynne Napatalung, Robert Wolk, Susan Anway, Samuel H. Zwillich   +7 more
doaj   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 8, Page e1155-e1177, August 2026.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity—Report of a Case and Review of the Literature

Frontiers in Neurology, 2017
Secondary autoimmunity is the most frequent adverse event occurring in almost every other alemtuzumab-treated multiple sclerosis patient. We report a case of a patient with relapsing-remitting multiple sclerosis who reported smooth, circular areas of ...
Julian Zimmermann, Timo Buhl, Marcus Müller   +2 more
doaj   +1 more source

Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1406-1419, August 2026.
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla, Roberta Fachini Jardim Criado, Kanokvalai Kulthanan, Emek Kocatürk, Ivan Cherrez‐Ojeda, Ana Maria Giménez‐Arnau, Marcus Maurer, Luis Felipe Ensina, Jonathan A. Bernstein, Michihiro Hide, Sergio Duarte Dortas Junior, Solange Oliveira Rodrigues Valle, Gabriela Dias, Paraskevi Xepapadak, Priyanshi Dangi, Indrashis Podder, Vesna Trajkova, Natasa Teovska Mitrevska, Iman Hamed Nasr, Bushra Al Hinai, Joanna Bartosińska, Dorota Krasowska, Paulina Szczepanik‐Kułak, Hilal Gungor, Deniz Ozceker, Kübra Çiçek, Esen Özkaya, Yasemin Erdem, Mücahit Ergün, Mustafa Tosun, Rabia Oztas Kara, Jie Li, Anastasia Allenova, Paulo Ricardo Criado   +33 more
wiley   +1 more source

Alopecia universalis in a patient under treatment of Ocrelizumab after switching from Rituximab (PP-06) [PDF]

Neurology Letters, 2023
Background: Ocrelizumab is a humanized monoclonal antibody, which acts as anti-CD20 antibody. It is used as a treatment of both relapsing-remitting MS and Progressive type.
Mahshid Mahyad, Mohammad Ali Nahayati, Mahboubeh Ebrahimian   +2 more
doaj  

Potential Treatment of Steroid‐Resistant Alopecia Areata Using Allogeneic Exosomes Derived From Adipose Tissue Mesenchymal Stromal Cells: A Case Report

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT A 31‐year‐old man with severe, corticosteroid‐resistant alopecia areata presented with substantial scalp hair loss (Severity of Alopecia Tool [SALT] score: 60%) despite a 1‐year regimen of topical corticosteroids, 5% minoxidil, and oral prednisolone. He was treated with allogeneic exosomes derived from adipose tissue mesenchymal stromal cells (
Masoumeh Kianpisheh, Mohsen Piroozhashemi, Shabnam Feshangchian‐Atashbar, Ali Ghamari, Alireza Shoae‐Hassani   +4 more
wiley   +1 more source

S3‐Leitlinie Diagnostik und Therapie der Alopecia areata – Teil 1: Diagnostik und Epidemiologie

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 7, Page 1000-1016, July 2026.
Zusammenfassung In dem vom Innovationsausschuss beim gemeinsamen Bundesausschuss (G‐BA) geförderten Projekt wurde von 2023 bis 2025 die S3‐Leitlinie zur Diagnostik und Therapie der Alopecia areata (AA) entwickelt. Die interdisziplinäre Expertengruppe bestand aus Vertretern der Deutschen Dermatologischen Gesellschaft, insbesondere aus der AG ...
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

S3 guideline diagnostics and therapy of alopecia areata – Part 1: Diagnostics and epidemiology

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 7, Page e1000-e1015, July 2026.
Summary In the project funded by the Innovation Committee at the G‐BA, the S3 guideline for the diagnosis and treatment of AA was developed between 2023 and 2025. The interdisciplinary expert panel consisted of representatives from the German Dermatological Society, in particular from the Pediatric Dermatology Working Group, the Professional ...
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient

Journal of Allergy and Clinical Immunology: Global
A 29-year-old male patient had severe atopic dermatitis (AD) and alopecia universalis (AU) that could not be controlled by using classic therapy. He started taking upadacitinib and achieved an excellent response for both his AD and AU. Thus, upadacitinib
Mara Giavina-Bianchi, MD, PhD, Pedro Giavina-Bianchi, MD, PhD   +1 more
doaj   +1 more source

Molecular signatures define alopecia areata subtypes and transcriptional biomarkers

EBioMedicine, 2016
Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. In this study, we conducted whole genome gene expression analysis of 96 human scalp skin biopsy specimens from AA or normal control subjects.
Ali Jabbari, Jane E. Cerise, James C. Chen, Julian Mackay-Wiggan, Madeleine Duvic, Vera Price, Maria Hordinsky, David Norris, Raphael Clynes, Angela M. Christiano   +9 more
doaj   +1 more source